Zepbound’s greater weight loss is a huge advantage for Eli Lilly, which is competing with Novo Nordisk for a larger share of the weight loss drug market.
Eikonizo Therapeutics, a biopharmaceutical company dedicated to developing disease-modifying therapies to improve the lives of people impacted by neurodegenerative and cardiorenal diseases announced ...
The most important investigation before the FTC right now is Novo Holdings’ proposed acquisition of Catalent. Some people might be expecting the FTC to abandon that investigation because of the ...
The partnership with Flagship will bring Novo Nordisk into closer contact with the VC's portfolio of 41 biotech companies, with the aim of creating a portfolio of "transformational" medicines for ...
Novo isn’t out of the woods yet in the US: there are continuing battles with PBMs, threats of new price transparency and controls, and even a legal claim that it colluded with its competitors to ...
Financial giants have made a conspicuous bearish move on Novo Nordisk. Our analysis of options history for Novo Nordisk (NYSE:NVO) revealed 14 unusual trades. Delving into the details, we found 35 ...
LONDON, Nov 18 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab said on Monday it has launched its popular obesity drug Wegovy in China, the world's second-largest pharmaceuticals market where ...
Novo Nordisk has plenty of avenues to pursue for growth. However, its competitive environment will soon become more challenging. Its valuation may also become a bit less favorable. But with such ...
According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market, where more than 180 ...